SAN JOSE, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended June 30, 2024. Recent Highlights Total revenue of $53.4 million for the second quarter of 2024, an increase of 61% compared to the prior period in 2023 U.S. handpiece and consumables revenue of $27.3 million for the se ...

REYKJAVIK, Iceland, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, will release financial results for first half of the year ended June 30, 2024, after U.S. markets close on Thursday, August 15, 2024, and will conduct a conference call with analysts to present the financial results and recent business highlights on Friday August 16, 2024, at 8:00 am EDT (12 noon GMT).   Live aud ...

KIRKLAND, Wash., Aug. 01, 2024 (GLOBE NEWSWIRE) -- MPS will report its results after the market closes on August 1, 2024 and host a question-and-answer webinar at 2:00 p.m. PT / 5:00 p.m. ET. The live event will be held via a Zoom webcast, which can be accessed at https://mpsic.zoom.us/j/97644523160. Q2 2024 Financial Summary (Unaudited) | --- | --- | --- | --- | --- | --- | --- | |------------------|---------------------|---------------------|-------|---------------------|---------------------|------------ ...

IBSRELA generates $35.4 million in net product sales revenue XPHOZAH generates $37.1 million in net product sales revenue Company ends Q2 with approximately $186 million in cash and investments Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported fin ...

– Delivers Total Annual Revenues of $5.8 Billion with 29% Growth – – Announces New $300 Million Share Repurchase Program – – Increases Annualized Dividend By 5% – Fiscal 2024 Annual Highlights Y/Y | --- | --- | --- | --- | --- | |-------------------------------------------------------------|----------------------------|------------------------------------------------|--------------------------------|----------------------------| | Total Revenues \n(in millions) \nReportedConstant Currency | (in millions) \n ...

WOODBURY, N.Y., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Research Frontiers Inc. (NASDAQ:REFR) announced its financial results for its second quarter of 2024. Management will host a conference call today at 4:30 p.m. Eastern Time to discuss its financial and operating results as well as recent developments. • Who: Joseph M. Harary, President & CEO • Date/Time: Thursday, August 1, 2024, 4:30 PM ET • Dial-in Information:1-888-334-5785 • Replay: Available on Friday, August 2, 2024 for 90 days at https://smartglass-ir ...

BridGene Eligible to Receive Up to $159 Million in Total Payments SAN JOSE, Calif., Aug. 1, 2024 /PRNewswire/ -- BridGene Biosciences, Inc., a leader in the discovery of small molecule drugs for traditionally "hard-to-drug" targets, today announced an expansion to its strategic collaboration and licensing agreement with Galapagos NV (Euronext: GLPG) (NASDAQ: GLPG). This new collaboration builds upon the partnership initiated in January 2024, focusing on the discovery of a highly selective oral SMARCA2 small ...

BOISE, Idaho, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Micron Technology, Inc. (NASDAQ:MU) announced today that company executives will participate in fireside chats at the following investor events: KeyBanc Capital Markets Technology Leadership Forum in Vail, Colorado on Monday, August 5, at 9:00 a.m. Mountain time.Deutsche Bank's 2024 Technology Conference in Dana Point, California on Wednesday, August 28, at 9:45 a.m. Mountain time. Live webcasts and subsequent replays of presentations can be accessed from Micr ...

Received productive feedback from Type C meeting with the FDA for the planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer On track to report overall survival results from randomized BRACELET-1 breast cancer study in H2 2024 Dosed first patient in new GOBLET study pancreatic cancer cohort; supported by funding from PanCAN Entered into collaboration with GCAR for inclusion of pelareorep in adaptive registration-enabling pancreatic cancer trial Cash position of $24.9 millio ...

WESTBURY, N.Y., Aug. 1, 2024 /PRNewswire/ -- Kensington Capital Acquisition Corp. V (NYSE: KCGI) ("Kensington"), a publicly-traded special purpose acquisition company, today announced that it will be unable to consummate an initial business combination and intends to dissolve and liquidate in accordance with the provisions of its Amended and Restated Memorandum and Articles of Association, as amended ("Liquidation"). As previously disclosed, Kensington had extended the date by which Kensington had to consum ...